medicine physicians say that we cannot set a target as we like and hit the target. But sudden control is by no means recommended. There are 2 important points. First, because no control means further aggravation, we must always try to reduce blood glucose levels. Second, although patients with good control may show some aggravation, they very rarely experience dramatic aggravation. We conducted a study in cooperation with the group of Professor Sekihara, from the 3rd Department of Internal Medicine, Yokohama City University. When we compared patients who showed a decrease and then an increase and patients who showed a decrease and remained low, the former developed retinopathy more frequently. If a patient shows a decrease and some aggravation is observed, we should hang in there. Do phototherapy and other necessary procedures, and patiently try to keep levels low. Then, the condition will not progress, and the risk will be relatively low. Do not allow high levels to persist. We must always bring high levels down, but it should be done slowly and the levels kept low. I think this is the best strategy.
Dr. Kurata: Then, it's time to end this session. Thank you very much, Dr. Yamashita.
Osaka
Chairman: Dr. Yozo Miyake (Department of Ophthalmology, Nagoya University) Dr. Miyake: Thank you, Dr. Yamashita. Your lecture covered the wide range of topics you study, starting from the present state of diabetes in Japan and including the discussion of future therapies. Are there any questions or comments?
Dr. Toshiaki Aritake (Seto City): Thank you for your fine lecture. I am practicing in a small clinic. I attended this seminar expecting to get some practical knowledge of drugs. I sometimes use ACE inhibitors such as tanatril and angiotensin blockers for type 2 diabetic retinopathy. Basically, we use them in cases with mild hypertension and nephropathy. I also use aspirin at times, in particular for end-stage retinopathy. My first question is: do you have experience in these types of treatment?
Next, we have recently heard much about thalidomide in newspapers and other media. It is used for multiple myeloma and leukemia, and the purpose is the suppression of vascular contraction. Are you aware of any reports on the use of thalidomide for retinopathy?
Dr. Yamashita: With respect to aspirin, we have done a study called ETDRS. As far as the evidence from this study showed, it is not effective in retinopathy. Aspirin has been shown to have substantial benefit in cardiovascular conditions. Oral use of 100 mg/day provides a prophylactic effect against cardiovascular diseases. So, according to available evidence, oral aspirin may be effective mainly on macroangiopathy. We need further studies to see whether or not it is really ineffective in retinopathy. It is possible that it may be effective in properly selected target populations. There are some reports on the benefit of aspirin in early stages of retinopathy. Such observations have not been confirmed by evidence from largescale studies. At least, oral aspirin does not aggravate retinopathy. It is considered a good treatment choice targeted at macroangiopathy.
With respect to thalidomide, I am not sure but I think a trial in the field of ophthalmology may be ongoing, expecting effectiveness in the inhibition of neovascularization. Although no such study is conducted in Japan, I have heard about a number of experimental studies. I speculate that a clinical trial may have been initiated. I am sorry I have not been following the developments in this direction.
Like aspirin, actual confirmation of efficacy awaits future large-scale epidemiological studies.
Dr. Miyake: Probably 10 years in the future, medication will be the mainstay of treatment for diabetes. There will be various developments. Theoretically we already have very good drugs, such as aldose reductase inhibitors, but the reality is not as rosy. What do you think is causing this situation?
Dr. Yamashita: My speculation is that the problem is a complete lack of efficacy evaluation in various forms of disease. There must be a drug that is effective in a given form of disease. The condition of retinopathy in individual patients must be understood on a molecular level, but we lack this knowledge. We have only very crude measures for evaluating which drug should be used in which patient. So, in large-scale epidemiological studies, any differences are likely to disappear. Patients having similar blood glucose levels often show completely different responses. The measures we have now do not properly evaluate the differences among such patients, and this results in a lack of efficacy. I think this is the first problem. The second problem lies in the evaluation of drugs. We have not sufficiently established the hierarchy of drug actions or the hierarchy in relation to forms of the disease. The study of Prof. Brownlee on oxidative stress provided clear-cut experimental results. We need to conduct that kind of study in an interdisciplinary, comprehensive, systemized way. Then, we will be able to say that things take place in such and such a sequence in a given group of patients, and thereby we could block this upstream reaction. Our science has not reached a point where we can use this strategy. We are not able to evaluate this hierarchy as yet. I think this is the second problem.
Dr. Naihoko Ogata (Kansai Medical University): Thank you for your lecture covering a truly wide range of topics. Diabetes involves complicated interactions among various factors, such as NO reduction, oxidative stress, angiotensin, cytokines and VEGF. Is there a way to identify which is the main factor determining the condition of an individual patient?
Dr. Yamashita: A problem at least lies in the study strategy. We need a clearer understanding of signal transduction in the cell on the molecular level. At present, we are looking at only crude changes. At the gene transcription level, for example, we should be able to see signals converging to a point and then spreading, in this way. Observed changes should be quite limited. If we can grasp these processes, we can say at least phenomenologically that a change in any factor, whether it is an elevation in VEGF or an elevation in PEDF, affects largely the same set of molecules, and the observed changes will be additions and subtractions among the effects of these factors. It is impossible at present to build a mathematical formula including all of these factors. Although microarray and proteome studies are heading in this direction, they are probably not sufficient. I speculate that future developments in the study of regulation at the gene expression level may be helpful. We have made much progress at the laboratory level, but there is a tremendous gap between laboratory findings and clinical application. If we can establish a method to evaluate these things, we may have a breakthrough. As for the study target, drugs regulating Question and Answer Sessions with Dr. Hidetoshi Yamashita various gene expression levels are essentially ideal, because they act on the root cause of various changes. Phenomenologically, it is good to look at crude changes, such as generation of active oxygen species and its consequences, and such an approach enables us to draw schemes in a relatively simple way. But it has not led to clinical efficacy. I think the study of intracellular signal transduction is essential, although I have no evidence.
Dr. Ogata: Thank you. What do you think about the clinical trials concerning the involvement of angiotensin II and platelet functions?
Dr. Yamashita: I feel that clinical trials on angiotensin II and PKCß inhibitors are targeted at cases with severe progression. If these agents are used for cases in somewhat earlier stages and are combined with blood glucose regulation, I expect they would be effective in delaying the onset of symptoms. For example, aspirin and other drugs regulating platelet functions may be effective, if they are used for a long period, starting from early stages. Even if we do not have the right method to evaluate drugs, we can pick up effective drugs by using carefully designed methods of drug administration. In other words, we have to use the second best way to evaluate drug effects, such as clinical observation of the fundus, blood glucose control, blood pressure etc. Starting medication early is a promising possibility. But in this case, a problem is the very long time required for a clinical trial. We need about 10 years to evaluate the onset of retinopathy, and we need to examine a very large number of patients. Probably we cannot plan such a clinical trial because of this problem. We may need to develop a practical way of clinically evaluating drugs. Through approaches like this, I hope that we will be able to use existing drugs more effectively.
Dr. Miyake: It is time to close this discussion. Thank you very much. As we have seen, the study of diabetic retinopathy is advancing steadily. I hope to see further developments in the near future. Thank you.
